keyword
MENU ▼
Read by QxMD icon Read
search

Rituximab

keyword
https://www.readbyqxmd.com/read/29143151/next-generation-anti-cd20-monoclonal-antibodies-in-autoimmune-disease-treatment
#1
Fanny Huynh Du, Elizabeth A Mills, Yang Mao-Draayer
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine-human chimera to which many patients develop antibodies and/or experience infusion-related reactions. A second generation of anti-CD20 mAbs has been designed to be more effective, better tolerated, and of lower immunogenicity. These include the humanized versions: ocrelizumab, obinutuzumab, and veltuzumab, and the fully human, ofatumumab...
November 16, 2017: Auto- Immunity Highlights
https://www.readbyqxmd.com/read/29142946/cd19-targeted-low-dose-rituximab-is-effective-in-the-management-of-refractory-phospholipase-a2-receptor-antibody-associated-membranous-nephropathy
#2
Raja Ramachandran, Ashok K Yadav, Vinod Kumar, Krishan L Gupta, Harbir S Kohli
No abstract text is available yet for this article.
January 2017: KI Reports
https://www.readbyqxmd.com/read/29142145/clinical-course-therapeutic-responses-and-outcomes-in-relapsing-mog-antibody-associated-demyelination
#3
Sudarshini Ramanathan, Shekeeb Mohammad, Esther Tantsis, Tina Kim Nguyen, Vera Merheb, Victor S C Fung, Owen Bruce White, Simon Broadley, Jeannette Lechner-Scott, Steve Vucic, Andrew P D Henderson, Michael Harry Barnett, Stephen W Reddel, Fabienne Brilot, Russell C Dale
OBJECTIVE: We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination. METHODS: We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disability Status Scale (EDSS), in 218 demyelinating episodes from 33 paediatric and 26 adult patients. RESULTS: The most common initial presentation in the cohort was optic neuritis (ON) in 54% (bilateral (BON) 32%, unilateral (UON) 22%), followed by acute disseminated encephalomyelitis (ADEM) (20%), which occurred exclusively in children...
November 15, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29141797/diagnosis-and-management-of-neuromyelitis-optica-spectrum-disorder-nmosd-in-iran-a-consensus-guideline-and-recommendations
#4
REVIEW
Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Amir Reza Azimi, Nasrin Asgari, Fahimeh H Akhoundi, Roya Abolfazli, Shekoofeh Alaie, Fereshteh Ashtari, Hormoz Ayromlou, Seyed Mohammad Baghbanian, Nahid Beladi Moghadam, Farzad Fatehi, Mohsen Foroughipour, Hamidreza Ghalyanchi Langroodi, Nastaran Majdinasab, Alireza Nickseresht, Abbas Nourian, Vahid Shaygannejad, Hamid Reza Torabi
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a relapsing neuro inflammatory disease of the central nervous system that typically presents with optic neuritis or myelitis and may cause severe disability. The diagnostic criteria have been updated and several immunosuppressive agents have been demonstrated to prevent acute exacerbations. As the disease rarely develops in a progressive course, management of acute attacks and proper prevention of exacerbations may change the long term out-come and prevent future disability...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29138885/delayed-recovery-of-serum-immunoglobulin-g-is-a-poor-prognostic-marker-in-patients-with-follicular-lymphoma-treated-with-rituximab-maintenance
#5
Yoshiharu Kusano, Masahiro Yokoyama, Norihito Inoue, Hirofumi Yamauchi, Anna Takahashi, Naoko Tsuyama, Yuko Mishima, Noriko Nishimura, Kengo Takeuchi, Yasuhito Terui, Kiyohiko Hatake
Clinical trials involving various treatment schedules for rituximab maintenance have been conducted for patients with follicular lymphoma (FL) and have not confirmed their impact on serum immunoglobulin (sIg) levels until the completion of maintenance. However, the long-term use of rituximab is a concern because of circulating plasma cell-depletion risk, suggesting that the mechanism of change in sIg levels after RM has not been determined. Additionally, the relationship between host humoral immunity and the prognosis of patients with B cell malignancies has not been determined...
November 14, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29138220/antibodies-targeting-surface-membrane-antigens-in-patients-with-chronic-graft-versus-host-disease
#6
Kathy S Wang, Haesook T Kim, Sarah Nikiforow, Alexander T Heubeck, Vincent T Ho, John Koreth, Edwin P Alyea, Philippe Armand, Bruce R Blazar, Robert J Soiffer, Joseph H Antin, Corey S Cutler, Jerome Ritz
Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant (HSCT) reflects a complex immune response resulting in chronic damage to multiple tissues. Previous studies indicated that donor B cells and the antibodies they produce play an important role in the development of cGVHD. To understand the pathogenic role of antibodies in cGVHD, we focused our studies on post-transplant production of IgG antibodies targeting cell surface antigens expressed in multiple cGVHD affected tissues, due to their potential functional impact on living cells in vivo...
November 14, 2017: Blood
https://www.readbyqxmd.com/read/29137592/isolated-v-lesion-in-an-abo-incompatible-kidney-transplant-recipient-receiving-rituximab
#7
Tomoaki Iwai, Junji Uchida, Kazuya Kabei, Shunji Nishide, Nobuyuki Kuwabara, Toshihide Naganuma, Norihiko Kumada, Yoshiaki Takemoto, Tatsuya Nakatani
We report an ABO-incompatible kidney transplant performed on a 69-year-old female patient, whose donor was her 69-year-old husband. The patient received an immunosuppressive protocol using rituximab without splenectomy. Renal biopsy was done on posttransplant day 8 due to poor early graft function, and an isolated v-lesion was found, which responded to steroid pulse therapy and gusperimus hydrochloride administration. Our results indicate that isolated v-lesions can occur in ABO-incompatible kidney transplant recipients receiving rituximab and that this finding should be treated as acute rejection...
November 15, 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29137104/tumor-and-bone-marrow-uptakes-on-18f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-predict-prognosis-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-rituximab-containing-chemotherapy
#8
Chin-Chuan Chang, Shih-Feng Cho, Hung-Pin Tu, Chia-Yang Lin, Ya-Wen Chuang, Shu-Min Chang, Wen-Ling Hsu, Ying-Fong Huang
The purpose of this study was to determine the relevance of standardized uptake value (SUV) on [F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), focusing on tumor and bone marrow, to disease outcomes based on progression-free survival (PFS) and overall survival (OS) in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-containing chemotherapy.We reviewed the records of patients with DLBCL who were diagnosed between September 2009 and January 2013 and underwent pretreatment whole-body FDG PET/CT scans...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29137041/efficacy-of-rituximab-combined-with-chop-for-treating-patients-with-diffuse-large-b-cell-lymphoma
#9
Xin Hu, Min Zeng, Shun-E Yang, Xiao Liang, Shan-Shan Ding, Li Guo, Shan Li, Shu-Juan Wen
BACKGROUND: This study aimed to evaluate the efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treating patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A total of 144 patients with DLBCL were randomly divided into intervention group and control group, 72 patients in each group. The patients in the control group received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, while the participants in the intervention group received R-CHOP...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29135832/prognostic-value-of-the-persistence-of-c1q-binding-anti-hla-antibodies-in-acute-antibody-mediated-rejection-in-kidney-transplantation
#10
Elodie Bailly, Dany Anglicheau, Gilles Blancho, Philippe Gatault, Vincent Vuiblet, Valérie Chatelet, Emmanuel Morelon, Paolo Malvezzi, Anne Parissiadis, Jérôme Tourret, Gwendaline Guidicelli, Johnny Sayegh, Christiane Mousson, Philippe Grimbert, Isabelle Top, Moglie Le Quintrec, Raj Purgus, Pierre François Westeel, Barbara Proust, Valérie Chabot, Yvon Lebranchu, Frédéric Dehaut, Matthias Büchler
BACKGROUND: The differential pathogenicity of anti-HLA donor-specific antibodies (DSAs) is not fully understood. The presence of complement-binding DSAs help better defining the prognosis of acute antibody-mediated rejection (ABMR). The evolution of these antibodies after the treatment of ABMR is unknown. METHODS: We included patients from the French multicenter RITUX ERAH study diagnosed with acute antibody-mediated rejection (ABMR) within the first year of renal transplantation, with circulating anti-HLA DSAs and treated randomly by rituximab or placebo (and intravenous immunoglobulins, plasma exchange)...
November 13, 2017: Transplantation
https://www.readbyqxmd.com/read/29135404/-bilateral-total-lung-lavage-in-a-patient-with-pulmonary-alveolar-proteinosis
#11
Müge Erbay, Yılmaz Bülbül, Funda Öztuna, Mehmet Kılıç, Neslihan Özçelik, Şafak Ersöz
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterised by alveolar accumulation of surfactant composed of proteins and lipids. Three main categories of PAP have been defined depending on the aetiology: primer/idiopathic, neonatal/congenital, secondary and exogenous/environmental exposure. Radiologically diffuse ground glass opacities, interlobular and intralobular septal thickening is seen. Although open lung biopsy is accepted as the gold standard in diagnosis, it can be diagnosed by showing bronchoalveolar lavage (BAL) fluid with a milky appearance and periodic acid-schiff (PAS) positive globules in biopsy with clinical and radiological findings...
September 2017: Tüberküloz Ve Toraks
https://www.readbyqxmd.com/read/29132903/progressive-multifocal-leukoencephalopathy-in-patients-receiving-rituximab-and-cyclophosphamide-after-haplo-identical-t-cell-replete-transplantation-and-review-of-the-literature
#12
REVIEW
R Salem, R Massoud, S S Kanj, M Hamdan, R Salman, A Bazarbachi, J El-Cheikh
John Cunningham virus (JCV) reactivation, occurring mainly in immunocompromised patients, leads to progressive multifocal leukoencephalopathy, an uncommon but lethal disease. JCV reactivation after T-cell replete haploidentical stem cell transplantation, in the pre-cyclophosphamide era, is poorly represented in the literature. We therefore describe two cases of acute myeloid leukemia who developed JCV reactivation after receiving cyclophosphamide and rituximab post haploidentical stem cell transplantation, and review the literature, aiming to a better understanding of the disease course and its risk factors...
November 10, 2017: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29132419/success-of-anti-cd20-monoclonal-antibody-treatment-for-severe-autoimmune-hemolytic-anemia-caused-by-warm-reactive-immunoglobulin-a-immunoglobulin-g-and-immunoglobulin-m-autoantibodies-in-a-child-a-case-report
#13
Houda Ajmi, Sameh Mabrouk, Saida Hassayoun, Haifa Regaieg, Minyar Tfifha, Chemli Jalel, Hadef Skouri, Noura Zouari, Saoussan Abroug
BACKGROUND: Autoimmune hemolytic anemia is rare in children. First-line therapies for this disease consist of corticosteroids and intravenously administered immunoglobulin that are effective in most patients. However, a small proportion of cases (5 to 10%) is refractory to these therapies and may represent a medical emergency, especially when hemolysis is due to warm immunoglobulin M. Recently, reports of the use of rituximab in adult autoimmune diseases have shown promising results. In children, there are few studies on the use of rituximab in the treatment for autoimmune hemolytic anemia, especially on its long-term efficacy and adverse effects...
November 14, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29132070/sixteen-year-history-of-rituximab-therapy-for-1085-pemphigus-vulgaris-patients-a-systematic-review
#14
REVIEW
Soheil Tavakolpour, HamidReza Mahmoudi, Kamran Balighi, Robabeh Abedini, Maryam Daneshpazhooh
Pemphigus vulgaris (PV) is a rare autoimmune disease due to the production of pathogenic autoantibodies directed against desmoglein 1 and 3, usually affecting both skin and mucous membranes. Recently, rituximab, a chimeric IgG1 monoclonal antibody which targets the CD20 molecules have been regarded as a promising treatment for PV. In this study, a systematic review was conducted to conclude on how and which PV patients could benefit from rituximab infusion. Search in PubMed results in 114 relevant studies, which met the criteria...
November 10, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29131039/adverse-reactions-of-antibody-therapy-for-primary-cutaneous-lymphomas-rituximab-brentuximab-vedotin-alemtuzumab-and-mogamulizumab
#15
I Saulite, E Guenova, W Hoetzenecker
Treatment of advanced PCLs is limited and rarely reaches complete remission despite aggressive treatment modalities, such as polychemotherapy with various adverse effects. However, several monoclonal antibodies drug agents in patients with advanced primary cutaneous lymphomas demonstrate promising efficacy and manageable safety profiles. The monoclonal antibodies drug agents have favourable tolerability compared with multi-agent cytotoxic chemotherapy. However, adverse effects manifest with a broad clinical spectrum, hence the markers of targeted therapies are not limited to tumour cells but found on tumour cells and also on benign T and/or B cells...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29131038/bullous-diseases
#16
Caroline Corbaux, Pascal Joly
Autoimmune bullous diseases are a heterogeneous group of blistering diseases affecting the skin and/or mucous membrane. Systemic corticosteroids, which are often associated with immunosuppressants, are the main treatment option for these diseases. The 2 main biologics used in the treatment of autoimmune bullous diseases are rituximab, especially in pemphigus and mucous membrane pemphigoid, and omalizumab in bullous pemphigoid. Rituximab is a promising therapeutic option in pemphigus and mucous membrane pemphigoid...
2018: Current Problems in Dermatology
https://www.readbyqxmd.com/read/29130134/is-it-possible-to-improve-prognostic-value-of-nccn-ipi-in-patients-with-diffuse-large-b-cell-lymphoma-the-prognostic-significance-of-comorbidities
#17
Darko Antic, Jelena Jelicic, Goran Trajkovic, Milena Todorovic Balint, Jelena Bila, Olivera Markovic, Ivan Petkovic, Vesna Nikolic, Bosko Andjelic, Vladislava Djurasinovic, Aleksandra Sretenovic, Mihailo Smiljanic, Vojin Vukovic, Biljana Mihaljevic
The prognostic value of the International Prognostic Index (IPI) has been re-evaluated in the rituximab-treated diffuse large B cell lymphoma (DLBCL) patients. Accordingly, National Comprehensive Cancer Network-IPI (NCCN-IPI) has been introduced to estimate prognosis of DLBCL patients. However, comorbidities that frequently affect elderly DLBCL patients were not analyzed. The aim of this study was to evaluate the prognostic significance of comorbidities using Charlson Comorbidity Index (CCI) in 962 DLBCL patients...
November 12, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29129978/a-case-of-peripheral-ulcerative-keratitis-associated-with-autoimmune-hepatitis
#18
Hamoon Eshraghi, Aria Mahtabfar, Mohammad H Dastjerdi
Purpose: To describe a case of peripheral ulcerative keratitis in the setting of autoimmune hepatitis and possible overlap syndrome with primary sclerosing cholangitis. Case Report: A 48-year-old African American female with autoimmune hepatitis with possible overlap syndrome with primary sclerosing cholangitis presented with tearing, irritation, and injection of the left eye that was determined to be peripheral ulcerative keratitis. The patient was treated with topical and systemic steroids, immunosuppressant drugs (azathioprine and mycophenolate mofetil), a biologic (rituximab), and surgery (conjunctival resection), and the peripheral ulcerative keratitis epithelialized but ultimately led to corneal perforation...
2017: Case Reports in Medicine
https://www.readbyqxmd.com/read/29128836/characterization-of-liposome-containing-spions-conjugated-with-anti-cd20-developed-as-a-novel-theranostic-agent-for-central-nervous-system-lymphoma
#19
S Saesoo, S Sathornsumetee, P Anekwiang, C Treetidnipa, P Thuwajit, S Bunthot, W Maneeprakorn, L Maurizi, H Hofmann, Ruktanonchai Uracha Rungsardthong, N Saengkrit
Despite advances in neuroscience cancer research during the past decades, the survival of cancer patients has only marginally improved and the cure remains unlikely. The blood-brain barrier (BBB) is a major obstacle protecting the entry of therapeutic agents to central nervous system, especially for primary central nervous system lymphoma (PCNSL). Thus, the use of small nanoparticle as a drug carrier may be new strategies to overcome this problem. In this study, we fabricated liposome consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with anti-CD20 (Rituximab; RTX)...
November 8, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29127674/pharmacotherapeutic-management-of-pediatric-lymphoma
#20
REVIEW
Christine Mauz-Körholz, Natascha Ströter, Julia Baumann, Ante Botzen, Katharina Körholz, Dieter Körholz
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) comprise approximately 15% of all childhood malignancies. Cure rates for both lymphoma entities have evolved tremendously during the last couple of decades, raising the 5-year survival rates to almost 100% for HL and to 85% for NHL. The mainstay therapy for both malignancies is still chemotherapy-with different regimens recommended for different types of disease. In HL, combined modality treatment, i.e., chemotherapy followed by radiotherapy, has long been the standard regimen...
November 10, 2017: Paediatric Drugs
keyword
keyword
5938
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"